Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context (original) (raw)

• Bjornstrom L, Sjoberg M . (2002). STAT as downstream targets of nongenomic estrogen receptor actions. Mol Endocrinol 16: 2202–2214.
  Article CAS PubMed Google Scholar
• Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ . (1995). Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 221: 706–718.
  Article CAS PubMed PubMed Central Google Scholar
• Brockman JL, Schroeder MD, Schuler LA . (2002). Prolactin activates the cyclin D1 promoter via the JAK2-STAT pathway. Mol Endocrinol 16: 774–784.
  Article CAS PubMed Google Scholar
• Bromberg J . (2002). Stat proteins and oncogenesis. J Clin Invest 109: 1139–1142.
  Article CAS PubMed PubMed Central Google Scholar
• Buettner R, Mora LB, Jove R . (2002). Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945–954.
  CAS PubMed Google Scholar
• Cao JS, Wood M, Liu Y, Hoffman T, Hyde J, Park-Sarge OK et al. (2004). Estradiol represses prolactin-induced expression of Na+/taurocholate cotransporting polypeptide in liver cells through estrogen receptor-α and STAT5a. Endocrinology 145: 1739–1749.
  Article CAS PubMed Google Scholar
• Clevenger CV, Furth PA, Hankinson SE, Schuler LA . (2003). Role of prolactin in mammary carcinoma. Endocr Rev 24: 1–27.
  Article CAS PubMed Google Scholar
• Cotarla I, Ren SX, Zhang Y, Gehan E, Singh B, Furth PA . (2004). Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 108: 665–671.
  Article CAS PubMed Google Scholar
• DaSilva L, Rui H, Erwin RA, Howard OM, Kirken RA, Malabarba MG et al. (1996). Prolactin recruits STAT1, STAT3 and STAT5 independent of conserved receptor tyrosines TYR402, TYR479, TYR515 and TYR580. Mol Cell Endocrinol 117: 131–140.
  Article CAS PubMed Google Scholar
• Eferl R, Wagner EF . (2003). AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859–868.
  Article CAS PubMed Google Scholar
• Faulds MH, Pettersson K, Gustafsson JA, Haldosen LA . (2001). Cross-talk between ERs and Stat5 is E2 dependent and involves two functionally separate mechanisms. Mol Endocrinol 15: 1929–1940.
  Article CAS PubMed Google Scholar
• Gee JM, Barroso AF, Ellis IO, Robertson JF, Nicholson RI . (2000). Biological and clinical associations of c-jun activation in human breast cancer. Int J Cancer 89: 177–186.
  Article CAS PubMed Google Scholar
• Goffin V, Bernichtein S, Touraine P, Kelly PA . (2005). Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 26: 400–422.
  Article CAS PubMed Google Scholar
• Gutzman JH, Nikolai SE, Rugowski DE, Watters JJ, Schuler LA . (2005). Prolactin and estrogen enhance the activity of AP-1 in breast cancer cells: role of ERK1/2-mediated signals to c-fos. Mol Endocrinol 19: 1765–1778.
  Article CAS PubMed Google Scholar
• Gutzman JH, Rugowski DE, Schroeder MD, Watters JJ, Schuler LA . (2004). Multiple kinase cascades mediate prolactin signals to AP-1 in breast cancer cells. Mol Endocrinol 18: 3064–3075.
  Article CAS PubMed Google Scholar
• Hennighausen L, Robinson GW . (2005). Information networks in the mammary gland. Nat Rev Mol Cell Biol 6: 715–725.
  Article CAS PubMed Google Scholar
• Horvai AE, Xu L, Korzus E, Brard G, Kalafus D, Mullen TM et al. (1997). Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc Natl Acad Sci USA 94: 1074–1079.
  Article CAS PubMed PubMed Central Google Scholar
• Humphreys RC, Hennighausen L . (1999). STAT5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ 10: 685–694.
  CAS PubMed Google Scholar
• Iavnilovitch E, Groner B, Barash I . (2002). Overexpression and forced activation of Stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Cell Growth Differ 1: 32–47.
  CAS Google Scholar
• Ilaria Jr RL, Hawley RG, Van Etten RA . (1999). Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 93: 4154–4166.
  CAS PubMed Google Scholar
• Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M et al. (1999). Increased AP-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5: 251–256.
  CAS PubMed Google Scholar
• Keely PJ . (2001). Ras and Rho protein induction of motility and invasion in T47D breast adenocarcinoma cells. Methods Enzymol 333: 256–266.
  Article CAS PubMed Google Scholar
• Levy DE, Darnell Jr JE . (2002). Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651–662.
  Article CAS PubMed Google Scholar
• Luo GY, Yu-Lee LY . (2000). Stat5b inhibits NFkappaB-mediated signaling. Mol Endocrinol 14: 114–123.
  CAS PubMed Google Scholar
• Milde-Langosch K, Bamberger AM, Methner C, Rieck G, Loning T . (2000). Expression of cell cycle-regulatory proteins rb, p16/MTS1, p27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of AP-1 family members. Int J Cancer 87: 468–472.
  Article CAS PubMed Google Scholar
• Milde-Langosch K, Roder H, Andritzky B, Aslan B, Hemminger G, Brinkmann A et al. (2004). The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res Treat 86: 139–152.
  Article CAS PubMed Google Scholar
• Nakamura T, Ouchida R, Kodama T, Kawashima T, Makino Y, Yoshikawa N et al. (2002). Cytokine receptor common beta subunit-mediated STAT5 activation confers NF-kappa B activation in murine proB cell line Ba/F3 cells. J Biol Chem 277: 6254–6265.
  Article CAS PubMed Google Scholar
• Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J et al. (2004). Stat-5 activation and breast cancer prognosis. J Clin Oncol 22: 2053–2060.
  Article CAS PubMed Google Scholar
• Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, Ali S . (2006). Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 66: 1824–1832.
  Article CAS PubMed Google Scholar
• Ormandy CJ, Horseman ND, Naylor MJ, Harris J, Robertson F, Binart N et al. (2001). Mammary gland development. Prolactin In: Horseman ND (ed). Kluwer Academic Publishers: Boston, pp. 219–232.
  Chapter Google Scholar
• Ren S, Cai HR, Li M, Furth PA . (2002). Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 21: 4335–4339.
  Article CAS PubMed Google Scholar
• Schroeder MD, Symowicz J, Schuler LA . (2002). Prolactin modulates cell cycle regulators in mammary tumor epithelial cells. Mol Endocrinol 16: 45–57.
  Article CAS PubMed Google Scholar
• Shaulian E, Karin M . (2002). AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131–E136.
  Article CAS PubMed Google Scholar
• Shemanko CS, Groner B . (2001). Transcription factors, cofactors and target genes mediating prolactin signals. Prolactin In: Horseman ND (ed). Kluwer Academic Publishers: Boston, pp. 381–404.
  Chapter Google Scholar
• Shuai K . (2000). Modulation of STAT signaling by STAT-interacting proteins. Oncogene 19: 2638–2644.
  Article CAS PubMed Google Scholar
• Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H . (2005). Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 24: 746–760.
  Article CAS PubMed Google Scholar
• Tworoger SS, Hankinson SE . (2006). Prolactin and breast cancer risk. Cancer Lett 243: 160–169.
  Article CAS PubMed Google Scholar
• Van't Veer LJ, Dai HY, Van de Vijver MJ, He YDD, Hart AAM, Mao M et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–536.
  Article CAS Google Scholar
• Vincenti MP . (2001). The matrix metalloproteinase and tissue inhibitor of metalloproteinase genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol Biol 151: 121–148.
  CAS PubMed Google Scholar
• Vonderhaar BK . (2000). Prolactin in Human Breast Cancer Development. Endocrine Oncology In: Ethier SP (ed). Humana Press: Totowa, NJ, pp. 101–120.
  Google Scholar
• Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al. (2005). Gene expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671–679.
  Article CAS PubMed Google Scholar
• Watson CJ . (2001). Stat transcription factors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 6: 115–127.
  Article CAS PubMed Google Scholar
• Weaver AM, Silva CM . (2006). Modulation of Stat5b activity in breast cancer cells by mutation of tyrosines within the transactivation domain. Mol Endocrinol 20: 2392–2405.
  Article CAS PubMed Google Scholar
• Yang E, Lerner L, Besser D, Darnell Jr JE . (2003). Independent and cooperative activation of chromosomal c-fos promoter by STAT3. J Biol Chem 278: 15794–15799.
  Article CAS PubMed Google Scholar
• Zhang X, Wrzeszczynska MH, Horvath CM, Darnell Jr JE . (1999). Interacting regions in Stat3 and c-Jun that participate in cooperative transcriptional activation. Mol Cell Biol 19: 7138–7146.
  Article CAS PubMed PubMed Central Google Scholar